Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

Diabetes Care. 1999 Jul;22(7):1137-43. doi: 10.2337/diacare.22.7.1137.

Abstract

Objective: The gut hormone glucagon-like peptide 1 (GLP-1) has insulinotropic and anorectic effects during intravenous infusion and has been proposed as a new treatment for type 2 diabetes and obesity. The effect of a single subcutaneous injection is brief because of rapid degradation. We therefore sought to evaluate the effect of infusion of GLP-1 for 48 h in patients with type 2 diabetes.

Research design and methods: We infused GLP-1 (2.4 pmol.kg-1.min-1) or saline subcutaneously for 48 h in randomized order in six patients with type 2 diabetes to evaluate the effect on appetite during fixed energy intake and on plasma glucose, insulin, glucagon, postprandial lipidemia, blood pressure, heart rate, and basal metabolic rate.

Results: The infusion resulted in elevations of the plasma concentrations of intact GLP-1 similar to those observed after intravenous infusion of 1.2 pmol.kg-1.min-1, previously shown to lower blood glucose effectively in type 2 diabetic patients. Fasting plasma glucose (day 2) decreased from 14.1 +/- 0.9 (saline) to 12.2 +/- 0.7 mmol/l (GLP-1), P = 0.009, and 24-h mean plasma glucose decreased from 15.4 +/- 1.0 to 13.0 +/- 1.0 mmol/l, P = 0.0009. Fasting and total area under the curve for insulin and C-peptide levels were significantly higher during the GLP-1 administration, whereas glucagon levels were unchanged. Neither triglycerides nor free fatty acids were affected. GLP-1 administration decreased hunger and prospective food intake and increased satiety, whereas fullness was unaffected. No side effects during GLP-1 infusion were recorded except for a brief cutaneous reaction. Basal metabolic rate and heart rate did not change significantly during GLP-1 administration. Both systolic and diastolic blood pressure tended to be lower during the GLP-1 infusion.

Conclusions: We conclude that 48-h continuous subcutaneous infusion of GLP-1 in type 2 diabetic patients 1) lowers fasting as well as meal-related plasma glucose, 2) reduces appetite, 3) has no gastrointestinal side effects, and 4) has no negative effect on blood pressure.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Appetite / drug effects*
  • Appetite Depressants / administration & dosage
  • Appetite Depressants / therapeutic use*
  • Blood Glucose / metabolism*
  • Blood Pressure / drug effects
  • C-Peptide / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Drug Delivery Systems
  • Energy Intake / drug effects
  • Glucagon / administration & dosage
  • Glucagon / blood
  • Glucagon / therapeutic use*
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptides
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Infusion Pumps
  • Insulin / blood
  • Lipids / blood
  • Middle Aged
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / therapeutic use*
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Pilot Projects
  • Postprandial Period
  • Protein Precursors / administration & dosage
  • Protein Precursors / therapeutic use*

Substances

  • Appetite Depressants
  • Blood Glucose
  • C-Peptide
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • Peptide Fragments
  • Peptides
  • Protein Precursors
  • glucagon-like peptide 1 (7-36)amide
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1
  • Glucagon
  • glucagon-like peptide 1 (7-37)